20 Jun 2025
QIAGEN and GENCURIX have announced a QIAcuity Digital PCR IVD assay development partnership.
Read More
18 Jun 2025
A new precision medicine collaboration aims to develop companion diagnostics for patients with mutCALR-expressing MPNs.
Read More
03 Jun 2025
New partnerships aim to support the growing demand for decentralized, non-invasive tools that advance precision medicine and help deliver more personalized care.
Read More
13 May 2025
QIAGEN has acquired Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests.
Read More
06 Sep 2024
QIAGEN has entered into a collaboration with Eli Lilly to support the development of a QIAstat-Dx in-vitro diagnostic (IVD) to detect APOE genotypes which can play a role in the diagnosis of Alzheimer’s disease.
Read More
29 Aug 2024
QIAGEN has expanded its Master Collaboration Agreement with AstraZeneca to develop and commercialize companion diagnostics for AstraZeneca’s future therapies being developed to address chronic diseases.
Read More
20 May 2022
QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.
Read More
24 Aug 2021
QIAGEN NV (Venlo, Países Bajos) y Sysmex Corporation (Kobe, Japón) firmaron una alianza estratégica global para el desarrollo y comercialización de diagnósticos complementarios del cáncer, que aprovechará tanto el liderazgo de QIAGEN en este campo como la tecnología Plasma-Safe-SeqS de Sysmex para secuenciación de próxima generación (NGS).
Read More
02 Jul 2021
QIAGEN N.V. (Venlo, Netherlands) and Sysmex Corporation (Kobe, Japan) have entered into a global strategic alliance for the development and commercialization of cancer companion diagnostics, which will leverage both QIAGEN’s leadership in this field and Sysmex’s Plasma-Safe-SeqS technology for next generation sequencing (NGS).
Read More
14 Aug 2020
QIAGEN N.V. (Venlo, Netherlands) plans to continue executing its growth strategy aimed at creating significant value for shareholders and other stakeholders after the voluntary public takeover offer by Thermo Fisher Scientific Inc. (Waltham, MA, USA) failed to achieve the minimum 66.67% acceptance threshold from QIAGEN shareholders.
Read More
13 Feb 2018
QIAGEN N.V. has entered into an agreement to acquire STAT-Dx, a privately-held company which develops next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven QIAGEN chemistries.
Read More
12 Jan 2017
QIAGEN N.V., a provider of sample and assay technologies, has acquired OmicSoft Corporation, which focuses on biomarker data management, visualization, and analysis.
Read More